Literature DB >> 16911073

Demonstration of lanthanum in liver cells by energy-dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopy.

Z Yang1, D Schryvers, F Roels, P C D'Haese, M E De Broe.   

Abstract

The appearance of lanthanum in liver cells as a result of the injection of lanthanum chloride into rats is investigated by advanced transmission electron microscopy techniques, including electron energy loss spectroscopy and high-resolution transmission electron microscopy. It is demonstrated that the lysosomes contain large amounts of lanthanum appearing in a granular form with particle dimensions between 5 and 25 nm, whereas no lanthanum could be detected in other surrounding cellular components.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16911073     DOI： 10.1111/j.1365-2818.2006.01601.x

Source DB:  PubMed          Journal:  J Microsc        ISSN： 0022-2720            Impact factor:   1.758


  9 in total

1.  Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.

Authors:  Alastair J Hutchison; M Edwina Barnett; Rolfdieter Krause; Jonathan T C Kwan; Ghodrat A Siami
Journal:  Nephron Clin Pract       Date:  2008-07-31

2.  Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.

Authors:  Stuart M Sprague; Hanna Abboud; Ping Qiu; Matthew Dauphin; Pinggao Zhang; William Finn
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-03       Impact factor: 8.237

Review 3.  Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.

Authors:  Stephen J P Damment; Michael Pennick
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

4.  A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate.

Authors:  Felix Bronner; Boris M Slepchenko; Michael Pennick; Stephen J P Damment
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate.

Authors:  Veerle P Persy; Geert J Behets; Marc E De Broe; Patrick C D'Haese
Journal:  Int J Nephrol Renovasc Dis       Date:  2009-04-01

6.  Comment on: 'Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child-Pugh stage A liver cirrhosis'.

Authors:  Michael Smyth; Birgitt Gellert; Raymond D Pratt
Journal:  NDT Plus       Date:  2009-06

Review 7.  Lanthanum carbonate: safety data after 10 years.

Authors:  Alastair J Hutchison; Rosamund J Wilson; Svetlana Garafola; John Brian Copley
Journal:  Nephrology (Carlton)       Date:  2016-12       Impact factor: 2.506

Review 8.  The Importance of Phosphate Control in Chronic Kidney Disease.

Authors:  Ken Tsuchiya; Taro Akihisa
Journal:  Nutrients       Date:  2021-05-14       Impact factor: 5.717

9.  Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review.

Authors:  Chenglong Zhang; Ji Wen; Zi Li; Junming Fan
Journal:  BMC Nephrol       Date:  2013-10-17       Impact factor: 2.388
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.